U.S. markets close in 3 minutes
  • S&P 500

    4,449.66
    +54.02 (+1.23%)
     
  • Dow 30

    34,773.36
    +515.04 (+1.50%)
     
  • Nasdaq

    15,053.04
    +156.20 (+1.05%)
     
  • Russell 2000

    2,260.67
    +42.11 (+1.90%)
     
  • Crude Oil

    73.19
    +0.96 (+1.33%)
     
  • Gold

    1,747.80
    -31.00 (-1.74%)
     
  • Silver

    22.58
    -0.33 (-1.43%)
     
  • EUR/USD

    1.1745
    +0.0049 (+0.42%)
     
  • 10-Yr Bond

    1.4100
    +0.0740 (+5.54%)
     
  • GBP/USD

    1.3727
    +0.0107 (+0.79%)
     
  • USD/JPY

    110.2750
    +0.4970 (+0.45%)
     
  • BTC-USD

    44,757.63
    +1,292.36 (+2.97%)
     
  • CMC Crypto 200

    1,122.47
    +13.55 (+1.22%)
     
  • FTSE 100

    7,078.35
    -5.02 (-0.07%)
     
  • Nikkei 225

    29,639.40
    -200.31 (-0.67%)
     

Cannara Biotech Inc. Reports Strong First Quarterly Profit Driven by Retail Debut

  • Oops!
    Something went wrong.
    Please try again later.
·5 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Third quarter revenue of $7.2 million, gross profit of $4.4 million, and net income of $1.7 million
showcases success of market strategy and operating model

MONTREAL, July 28, 2021 /CNW Telbec/ - Cannara Biotech Inc. ("Cannara" or the "Company") (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB), a vertically integrated producer of premium-grade cannabis and derivative products with two Quebec-based mega cultivation facilities spanning over 1.65 million sq. ft., announced today its third quarter financial and operating results for the three and nine month periods ended May 31, 2021. All financial results are reported in Canadian dollars, unless otherwise noted.

Cannara Biotech Inc. Logo (CNW Group/Cannara Biotech Inc.)
Cannara Biotech Inc. Logo (CNW Group/Cannara Biotech Inc.)

Third Quarter 2021 Highlights

  • Total revenue of $7.2 million, including $5.9 million in cannabis sales, net of excise tax.

  • Gross profit of $3.5 million or 49% and $4.4 million or 62% after fair value adjustments.

  • Operating expenses are down by 27% to $2.2 million in Q3 2021 from $3.0 million in Q3 2020.

  • Adjusted EBITDA of $1.7 million or 23%.

  • Net income of $1.7 million or 24%.

  • Sold approximately 1,400 kg of cannabis it had in inventory from previous harvests for a total value of $1,265,000.

  • Uplisted to the TSX Venture (TSXV) from the Canadian Stock Exchange (CSE) on April 8, 2021, reflecting Company's maturity and the commercialization of its operational strategy.

"This quarter's results are a testament to our strategy's efficacy and management's focus," said Zohar Krivorot, President & Chief Executive Officer of Cannara. "With impressive revenue generation in our first full quarter of sales in retail market, the closing of our additional $5 million private placement and headline acquisition of our latest one million square foot facility in Valleyfield, we are now positioned among the country's leading cannabis producers."

"Our positive net income and strong gross margins confirm our operational excellence, uniquely lean company structure, and continued growth," said Nicholas Sosiak, Chief Financial Officer of Cannara. "Cannara's core competence is our differentiated model that underscores our ability to excel at maximizing the use of our resources. We are executing against this proven model, as we continue to scale our business in the next chapter of our growth roadmap."

Highlights Subsequent to Quarter End

  • Acquired a one million sq. ft. state-of-the-art cultivation facility from The Green Organic Dutchman Ltd. ("TGOD") for $27 million, providing Cannara the ability to reach an annual cultivation capacity of 125,000 kg of premium-grade cannabis.

  • Closed private placements of $24.3 million priced at a premium to the market price at time of the transaction and $5.7 million in convertible debentures bearing interest at 4% to fund the acquisition of the Valleyfield facility and related working capital expenditures.

  • Converted the Company's existing $5 million credit facilities bearing interest at 13% into a convertible debenture bearing 4% interest and subject to a statutory hold period of four months and one day from the date of issuance.

  • Granted an aggregate total of 425,000 stock options to certain employees at an exercise price of $0.18 per common share, subject to certain vesting conditions.

  • Launched an additional six SKUs in market under the Tribal and Orchid CBD brands in June 2021.

  • Released three new cannabis genetics, Cuban Linx, Do-Si-Dos, CBD Runtz, in dried flower and pre-roll formats.


Three-month periods ended


Nine-month periods ended

Selected Financial Highlights

May 31,
2021

May 31,
2020


May 31,
2021

May 31,
2020







Gross revenue1

$

6,716,598

$

751,509


$

10,020,039

$

1,933,592

Other income

442,733

12,397


765,227

31,996


7,159,331

763,906


10,785,266

1,965,588







Gross profit, before fair value adjustments

3,506,278

646,628


5,300,685

1,616,456

%

49%

85%


49%

82%

Gross profit

4,419,124

715,741


6,016,973

1,685,569

%

62%

94%


56%

86%







Operating expenses

2,159,809

2,974,501


7,326,384

10,152,617

Net finance expense

561,513

248,343


1,350,575

718,127







Net income (loss)

$

1,697,802

$

(2,507,103)


$

(2,659,986)

$

(9,185,175)

%

24%

-328%


-25%

-467%







Adjusted EBITDA

$

1,671,974

$

(2,215,049)


$

(966,307)

$

(6,891,027)

%

23%

-290%


-9%

-351%







Basic earnings (loss) per share

$

0.01

$

(0.01)


$

(0.01)

$

(0.01)

Diluted earnings (loss) per share

$

0.01

$

(0.01)


$

(0.01)

$

(0.01)








May 31, 2021


August 31, 2020







Cash


$

5,563,680



$

7,771,177

Accounts receivable


2,394,169



26,370

Biological assets


2,187,590



1,313,370

Inventory


3,368,714



928,351







Working capital


9,165,402



7,052,904







Total assets


57,925,722



54,850,428

Total current liabilities


4,697,602



3,476,952

Total non-current liabilities


16,732,890



13,008,615













1Gross revenue included revenue from sale of goods, net of excise taxes, and lease revenues.

A copy of the Management Discussion & Analysis and Financial Statements for Q3 2021 can be downloaded from Cannara's SEDAR profile and on investors.cannara.ca.

About Cannara Biotech Inc.

Cannara Biotech Inc. (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB) is a vertically integrated producer of premium–grade cannabis and cannabis–derivative products for the Quebec and Canadian markets. The Company's main focus is to deliver craft-quality "AAAA" products at disruptive retail pricing, continuous rotation of rare genetics, community responsiveness and transparency to collectively add to its value proposition. Leveraging the provinces low electricity and labor rates, Cannara owns two mega Quebec–based facilities spanning over 1,650,000 sq. ft., providing up to 125,000kg of annualized cultivation output. For more information, please visit cannara.ca.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding "Forward-Looking" Information

This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Cannara Biotech Inc.

Cision
Cision

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/July2021/28/c2050.html